Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma

Australas J Dermatol. 2022 Aug;63(3):e222-e225. doi: 10.1111/ajd.13881. Epub 2022 Jun 6.

Abstract

Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous tumour of neuroendocrine cell origin, which can grow rapidly and metastasise early. Localised disease is treated with surgery and radiotherapy. Disease that reaches a more advanced stage can be treated with a variety of different treatment modalities including surgery, radiotherapy, chemotherapy, radionuclide therapy, immunotherapy, and intralesional therapy. We report a case of a patient who had exhausted all local and systemic treatment options and who subsequently had an exceptional response to intralesional injection of Talimogene laherparepvec (TVEC).

Keywords: cancer intervention; chemotherapy

Publication types

  • Case Reports

MeSH terms

  • Biological Products
  • Carcinoma, Merkel Cell* / therapy
  • Herpesvirus 1, Human
  • Humans
  • Melanoma* / pathology
  • Oncolytic Virotherapy* / methods
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology
  • Treatment Outcome

Substances

  • Biological Products
  • talimogene laherparepvec